Inquiry Basket
Gly3-VC-PAB-MMAE is a drug-linker conjugate for ADC consisting of a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE).
| Catalog Number | Size | Price | Quantity | ||
|---|---|---|---|---|---|
| BADC-01340 | 2 mg | $1099 | Inquiry |
Gly3-VC-PAB-MMAE is a sophisticated peptide-drug conjugate (PDC) designed for targeted cancer therapy, particularly in the development of antibody-drug conjugates (ADCs). The compound consists of a glycine tripeptide (Gly3) linked to a cleavable peptide linker (VC), para-aminobenzoic acid (PAB), and the potent cytotoxic agent monomethyl auristatin E (MMAE). The Gly3 peptide acts as a spacer, while the VC linker ensures that MMAE is released selectively inside cancer cells following internalization of the ADC. MMAE disrupts microtubule function, leading to cell cycle arrest and apoptosis, making Gly3-VC-PAB-MMAE a critical component for precise, targeted chemotherapy. This structure enables high specificity, reducing off-target toxicity and improving the therapeutic index of cancer treatments.
One of the key applications of Gly3-VC-PAB-MMAE is in the treatment of a wide range of malignancies, including solid tumors and hematological cancers. The VC linker is designed to be cleaved by enzymes typically found in the acidic tumor microenvironment, ensuring the release of MMAE specifically within cancer cells. This targeted delivery of the cytotoxic drug minimizes damage to healthy tissues, which is a major limitation of conventional chemotherapy. As part of ADCs, Gly3-VC-PAB-MMAE significantly enhances the precision of drug delivery, offering a more effective and less toxic alternative to traditional chemotherapeutic agents.
Gly3-VC-PAB-MMAE is also being explored for its potential use in combination therapies. Research indicates that when used alongside immune checkpoint inhibitors or other targeted therapies, Gly3-VC-PAB-MMAE can enhance the overall therapeutic response. By inducing cell death in cancer cells and simultaneously modulating the tumor microenvironment, it may increase the susceptibility of tumors to other treatments. This combination approach is particularly beneficial for cancers that are resistant to standard therapies, such as certain types of breast cancer or non-small cell lung cancer. In this context, Gly3-VC-PAB-MMAE could help overcome treatment resistance and improve clinical outcomes.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
